Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | DDO | Q99489 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767751 | 0.87 | ALOX5 (0.57) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| SCHEMBL29875597 | 0.87 | ALOX5 (0.57) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| SCHEMBL417540 | 0.82 | ALOX5 (0.64) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| SCHEMBL6193534 | 0.79 | ALOX5 (0.54) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| SCHEMBL7193003 | 0.78 | KDM4E (0.46) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| SCHEMBL21686469 | 0.77 | ALOX5 (0.55) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| SCHEMBL27502588 | 0.77 | ALOX5 (0.58) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| SCHEMBL1464939 | 0.77 | HPGD (0.53) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| Alanine SCHEMBL28826582 | 0.76 | ALOX5 (0.57) | ALOX5KDM4ELMNATP53L3MBTL1 | |
| SCHEMBL9407553 | 0.76 | ALOX5 (0.54) | ALOX5KDM4ELMNATP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819697-B1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-8008320-B2 | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors | Johannes Gutenberg-Universitatis (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1819697-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | Johannes Gutenberg-Universität Mainz (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006061212-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | Johannes Gutenberg-Universität Mainz (DE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | FLT4, KDR, FLT1 | ALOX5 1160/4885KDM4E 179/4885LMNA 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.